Pathfinder Cell Therapy Accounts Payable

Pathfinder Cell Therapy (PFND) currently reports a accounts payable of $330K as of September 2015. That compares with $190K in the prior-year period — up 73.4% year over year. Use the charts on this page to explore Pathfinder Cell Therapy's accounts payable history and peer comparisons.

Pathfinder Cell Therapy's accounts payable increased from $190K to $330K — a 73.4% year-over-year increase (period ending September 2015). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pathfinder Cell Therapy reported $330K in accounts payable as of September 2015. That compares with $190K in the prior-year period — up 73.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $330K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Pathfinder Cell Therapy, and consider following PFND for alerts when major investors trade the stock.

Pathfinder Cell Therapy is classified in the Healthcare sector. On accounts payable, it currently shows $330K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PFND with unrelated industries.